Madrigal Pharmaceuticals Inc
$298.87
(as of Jul 3, 1:00 PM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Ticker Information for Madrigal Pharmaceuticals Inc
Stock Price
$298.87
Ticker Symbol
MDGL
Exchange
NASDAQ
Industry Information for Madrigal Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Company Description for Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Fundamentals for Madrigal Pharmaceuticals Inc
Market Capitalization
$6,635,900,416
EBITDA
$-423,841,984
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-17.84
Earnings per Share Estimate Next Year
Profit Margin
-123.38%
Shares Outstanding
22,203,300
Percent Owned by Insiders
7.73%
Percent Owned by Institutions
108.21%
52-Week High
52-Week Low
Technical Indicators for Madrigal Pharmaceuticals Inc
Analyst Ratings for Madrigal Pharmaceuticals Inc
Strong Buy
10
Buy
3
Hold
1
Sell
1
Strong Sell
0
News About Madrigal Pharmaceuticals Inc
Jul 2, 2025, 5:01 AM EST
Investing.com - Madrigal Pharmaceuticals (NASDAQ:MDGL), currently trading near $300 with analysts seeing up to 80% upside potential according to InvestingPro data, will present a comparative meta-analysis of its drug Rezdiffra against glucagon receptor agonists in MASLD and MASH at an upcoming medical conference on Saturday, July 12.
See more.
Jul 2, 2025, 2:46 AM EST
Madrigal Pharmaceuticals (NASDAQ:MDGL) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. See more.
Jun 26, 2025, 3:42 PM EST
[Human Internal Digestive Organ Liver Anatomy]
See more.
Jun 24, 2025, 12:45 PM EST
Madrigal Pharmaceuticals Inc. See more.